Pennant Group Reports Strong Q4 & Full-Year 2025 Results, Issues Positive 2026 Guidance
PNTG sits 53% above its 52-week low of $21.18.
Summary
The Pennant Group reported strong financial results for Q4 and full-year 2025, with significant revenue and earnings growth across its home health, hospice, and senior living segments, alongside optimistic 2026 guidance.
Key Events · Earnings and Guidance · PNTG
-
Strong Q4 2025 Performance
Reported a 53.2% increase in total revenue to $289.3 million and a 41.7% rise in adjusted diluted EPS to $0.34 compared to the prior year quarter.
-
Robust Full-Year 2025 Growth
Achieved a 36.3% increase in total revenue to $947.7 million and a 25.5% increase in adjusted diluted EPS to $1.18 for the full year.
-
Positive 2026 Guidance Issued
Provided an optimistic outlook for 2026, anticipating total revenue between $1,133.6 million and $1,171.8 million and adjusted diluted EPS between $1.26 and $1.36.
-
Operational Momentum
Noted significant growth in home health admissions (44.1% full year) and hospice average daily census (28.6% full year), along with a 200 basis point increase in senior living occupancy for Q4.
Analysis · PNTG · Industrial Applications And Services
The Pennant Group delivered robust financial results for the fourth quarter and full-year 2025, demonstrating significant growth in revenue and adjusted earnings across its home health, hospice, and senior living segments. The company's positive 2026 guidance, projecting continued double-digit growth, reinforces investor confidence, especially as the stock trades near its 52-week high. This performance highlights successful operational execution, strategic acquisitions, and strong organic growth in key service areas.
At the time of this filing, PNTG was trading at $32.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $21.18 to $33.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.